Analytical Evaluation of an Automated Immunoassay for Cardiac Troponin I: The Vidas Troponin I Assay
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 378849379 | ||
| 003 | CHVBK | ||
| 005 | 20180305123319.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 161128e20030919xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1515/CCLM.2003.209 |2 doi |
| 035 | |a (NATIONALLICENCE)gruyter-10.1515/CCLM.2003.209 | ||
| 245 | 0 | 0 | |a Analytical Evaluation of an Automated Immunoassay for Cardiac Troponin I: The Vidas Troponin I Assay |h [Elektronische Daten] |c [Francesca Di Serio, Paolo Trerotoli, Gabriella Serio, Lucia Varraso, Nicola Pansini] |
| 520 | 3 | |a Cardiac troponin I (cTnI) is a sensitive and specific biochemical marker of myocardial damage. We assessed the analytical performance of the Vidas® Troponin I assay (Biomerieux). Controls and serum pools were used to determine the precision, analytical sensitivity and linearity; 97.5 and 99.5 percentiles concentrations were determined from the reference population. Fifty corresponding samples of serum and plasma (lithium-heparin) were tested and the results compared. The in vitro stability of serum and plasma samples was assessed at 20 °C, 4 °C and -20 °C, respectively. Samples of serum were used to assess the agreement between the Vidas® Troponin I method and the revised Dimension RxL cTnI method (Dade-Behring). The total imprecision (CVs) was 13.1-5.2% for concentrations ranging between 0.25 and 19.8 µg/l cTnI. The lower detection limit was <0.1 µg/l. The upper reference limit (97.5 and 99.5 percentiles) was 0.11 µg/l and 0.12 µg/l, respectively (CV >10%). The assay was linear up to 21 g/l. The concentrations in lithium-heparin plasma were higher compared to those of the matched serum samples. The study of the agreement between the Vidas and Dimension RxL cTnI assays showed a total concordance of 96% with a bias value of -0.042. The Vidas® Troponin I test is a fast, precise and sensitive method for the determination of cTnI. Clin Chem Lab Med 2003; 41(10): 13631368 | |
| 540 | |a Copyright © 2003 by Walter de Gruyter GmbH & Co. KG | ||
| 690 | 7 | |a Medical equipment & techniques |2 nationallicence | |
| 690 | 7 | |a Medical diagnosis |2 nationallicence | |
| 690 | 7 | |a Diseases & disorders |2 nationallicence | |
| 700 | 1 | |a Serio |D Francesca Di |4 aut | |
| 700 | 1 | |a Trerotoli |D Paolo |4 aut | |
| 700 | 1 | |a Serio |D Gabriella |4 aut | |
| 700 | 1 | |a Varraso |D Lucia |4 aut | |
| 700 | 1 | |a Pansini |D Nicola |4 aut | |
| 773 | 0 | |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/10(2003-09-19), 1363-1368 |x 1434-6621 |q 41:10<1363 |1 2003 |2 41 |o cclm | |
| 856 | 4 | 0 | |u https://doi.org/10.1515/CCLM.2003.209 |q text/html |z Onlinezugriff via DOI |
| 908 | |D 1 |a research article |2 jats | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1515/CCLM.2003.209 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Serio |D Francesca Di |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Trerotoli |D Paolo |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Serio |D Gabriella |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Varraso |D Lucia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Pansini |D Nicola |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/10(2003-09-19), 1363-1368 |x 1434-6621 |q 41:10<1363 |1 2003 |2 41 |o cclm | ||
| 900 | 7 | |b CC0 |u http://creativecommons.org/publicdomain/zero/1.0 |2 nationallicence | |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-gruyter | ||